Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
NCT ID: NCT00334152
Last Updated: 2017-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
515 participants
INTERVENTIONAL
2006-03-31
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
NCT00326248
Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
NCT00600990
A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
NCT00108095
A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers
NCT00404274
A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)
NCT00539721
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
casopitant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have not smoked for the last 6 months.
* Having certain abdominal, breast, thyroid or shoulder surgery.
Exclusion Criteria
* Have certain pre-existing medical conditions or take certain medications.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Fairhope, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Montgomery, Alabama, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Arcadia, California, United States
GSK Investigational Site
Glendale, California, United States
GSK Investigational Site
Laguna Hills, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Boca Raton, Florida, United States
GSK Investigational Site
Melbourne, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
West Palm Beach, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Kansas City, Kansas, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Royal Oak, Michigan, United States
GSK Investigational Site
Mineola, New York, United States
GSK Investigational Site
New Hyde Park, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Charlottesville, Virginia, United States
GSK Investigational Site
Winchester, Virginia, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Aalst, , Belgium
GSK Investigational Site
Brasschaat, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Jihlava, , Czechia
GSK Investigational Site
Olomouc, , Czechia
GSK Investigational Site
Pardubice, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Marburg, Hesse, Germany
GSK Investigational Site
Neubrandenburg, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Wismar, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Ludwigshafen am Rhein, Rhineland-Palatinate, Germany
GSK Investigational Site
Homburg, Saarland, Germany
GSK Investigational Site
Halle, Saxony-Anhalt, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Kwun Tong, , Hong Kong
GSK Investigational Site
Pokfulam, , Hong Kong
GSK Investigational Site
Shatin, New Territories, , Hong Kong
GSK Investigational Site
Sheung Shui, New Territories, , Hong Kong
GSK Investigational Site
Lahore, , Pakistan
GSK Investigational Site
Manila, , Philippines
GSK Investigational Site
Quezon City, , Philippines
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Perm, , Russia
GSK Investigational Site
Saint Petersburgh, , Russia
GSK Investigational Site
A Coruña, , Spain
GSK Investigational Site
Badalona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Mataró, , Spain
GSK Investigational Site
Pamplona, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
GSK Investigational Site
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKT102552
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.